FDA approves first drug for rare neurological disorder
The US Food and Drug Administration approved a new drug for Alexander disease after decades of research.
The rare condition affects fewer than one person per million globally and causes severe mobility loss and seizures in patients. It stems from a genetic fault creating abnormal protein tangles that damage brain helper cells and myelin sheaths.
Scientists developed zilganersen to lower levels of the faulty protein directly within the body instead of just managing difficult symptoms. Clinical trials involving fifty four patients across thirteen sites showed motor skills stabilized or improved for younger participants.
Some treated patients experienced mild side effects like vomiting or headaches. Serious issues were less common than in the control group.
The FDA warned that rare cases of aseptic meningitis occurred. Overall safety standards were met after treatments lasting over a year.
This custom drug uses small DNA bits to suppress GFAP production. It is given via spinal injection every three months by professionals.
It does not reverse the condition or make it vanish. However, it significantly slows progression and improves symptoms for affected families globally.
“The fog's being lifted on her brain, and her personality gets a chance to come out more and more.”